Abstract
摘要
相似文献
1
Overdue process.
Nat Biotechnol. 2004 Nov;22(11):1329. doi: 10.1038/nbt1104-1329.
2
BIO and biogenerics.
Nat Biotechnol. 2005 Jan;23(1):17; discussion 17. doi: 10.1038/nbt0105-17a.
3
Biogenerics standoff.
Nat Biotechnol. 2004 Nov;22(11):1343-6. doi: 10.1038/nbt1104-1343.
4
Trials and error.
Nat Biotechnol. 2005 Dec;23(12):1481. doi: 10.1038/nbt1205-1481.
5
A critical tipping point.
US News World Rep. 2002 Apr 22;132(13):72.
6
The drive to reform the FDA gains momentum.
Hosp Formul. 1995 Mar;30(3):178, 177.
7
Generic drug approval: a US perspective.
Curr Med Res Opin. 2011 Mar;27(3):541-5. doi: 10.1185/03007995.2010.548374. Epub 2011 Jan 10.
8
FDA and EMEA pool scientific advice.
Nat Biotechnol. 2004 Dec;22(12):1490-1. doi: 10.1038/nbt1204-1490.
9
FDA embraces risk-management approach.
Nat Biotechnol. 2003 Oct;21(10):1120-1. doi: 10.1038/nbt877.
10
Getting SMART (submission management and review tracking) drug review in the computer age.
FDA Consum. 1995 Oct;29(8):6-9.
Zotero 插件